Giredestrant
WO42133
Phase 2 small_molecule completed
Quick answer
Giredestrant for Early Breast Cancer is a Phase 2 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Early Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed